S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon

Axos Financial (AX) Earnings Date, Estimates & Call Transcripts

$50.30
+1.09 (+2.21%)
(As of 04/19/2024 ET)

Earnings Summary

Upcoming
Earnings Date
Apr. 30
After Market Closes
Confirmed
Actual EPS
(Jan. 30)
$1.60 Beat By $0.21
Consensus EPS
(Jan. 30)
$1.39
Skip Charts & View Estimated and Actual Earnings Data

AX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Axos Financial Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242$1.25$1.33$1.29
Q2 20242$1.10$1.35$1.23
Q3 20242$1.70$1.78$1.74
Q4 20241$1.74$1.74$1.74
FY 20247$5.79$6.20$6.00
Q1 20251$1.83$1.83$1.83
Q2 20251$1.76$1.76$1.76
Q3 20251$1.71$1.71$1.71
Q4 20251$1.80$1.80$1.80
FY 20254$7.10$7.10$7.10
Q1 20261$1.89$1.89$1.89
Q2 20261$1.90$1.90$1.90

AX Earnings Date and Information

Axos Financial last released its quarterly earnings results on January 30th, 2024. The reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.21. The business earned $352.74 million during the quarter, compared to analyst estimates of $247.43 million. Its revenue was up 54.5% on a year-over-year basis. Axos Financial has generated $6.78 earnings per share over the last year ($6.78 diluted earnings per share) and currently has a price-to-earnings ratio of 7.4. Earnings for Axos Financial are expected to grow by 7.60% in the coming year, from $6.45 to $6.94 per share. Axos Financial has confirmed that its next quarterly earnings report will be published on Tuesday, April 30th, 2024. Axos Financial will be holding an earnings conference call on Tuesday, April 30th at 5:00 PM Eastern. Interested parties can register for or listen to the call. or dial in at 877-660-6853 with passcode "13745514".

Axos Financial Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
4/30/2024
Confirmed)
-------  
1/30/2024Q2 2024$1.39$1.60+$0.21$0.58$247.43 million$352.74 million      
10/26/2023Q1 2024$1.35$1.41+$0.06$1.44$241.52 million$245.66 million
7/27/2023Q4 2023$1.27$1.50+$0.23$1.54$227.98 million$236.46 million    
7/27/2023Q4 2023$1.27$1.50+$0.23$1.54$228.66 million$236.46 million    
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$222.94 million$231.23 million      
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
4/27/2023Q3 2023$1.21$1.35+$0.14$1.38$221.94 million$231.23 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$217.27 million$228.24 million      
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
1/26/2023Q2 2023$1.23$1.38+$0.15$1.41$216.37 million$228.24 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
Tiny Biotech Stock Wins $75 Billion Patent (Ad)

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
10/27/2022Q1 2023$1.13$1.18+$0.05$1.39$197.50 million$207.68 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$179.34 million$192.50 million    
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million    
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
8/4/2022Q4 2022$1.02$1.12+$0.10$1.28$180.82 million$192.51 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$176.90 million$178.31 million    
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
4/28/2022Q3 2022$0.99$1.05+$0.06$1.08$177.24 million$178.31 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.54 million$176.36 million    
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
Tiny Biotech Stock Wins $75 Billion Patent (Ad)

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>
1/27/2022Q2 2022$0.98$1.04+$0.06$1.08$177.91 million$176.36 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/28/2021Q1 2022$0.87$1.03+$0.16$1.07$164.89 million$173.34 million
10/27/2021Q3 2021$0.89$0.99+$0.10$1.07$167.06 million$173.34 million    
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/29/2021Q4 2021$0.86$0.92+$0.06$0.94$159.91 million$158.46 million
7/28/2021Q2 2021$0.87$0.90+$0.03$0.94$159.91 million$158.46 million    
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/29/2021Q3 2021$0.86$0.92+$0.06$0.95$159.43 million$159.56 million
4/28/2021Q1 2021$0.86$0.89+$0.03$0.95$159.43 million$159.56 million  

Axos Financial Earnings - Frequently Asked Questions

When is Axos Financial's earnings date?

Axos Financial has confirmed that its next quarterly earnings data will be published on Tuesday, April 30th, 2024. Learn more on AX's earnings history.

Did Axos Financial beat their earnings estimates last quarter?

In the previous quarter, Axos Financial (NYSE:AX) reported $1.60 earnings per share (EPS) to beat the analysts' consensus estimate of $1.39 by $0.21. Learn more on analysts' earnings estimate vs. AX's actual earnings.

How can I listen to Axos Financial's earnings conference call?

The conference call for Axos Financial's latest earnings report can be listened to online. Listen to Conference Call

How can I read Axos Financial's conference call transcript?

The conference call transcript for Axos Financial's latest earnings report can be read online. Read Transcript

How can I view Axos Financial's earnings report?

Axos Financial's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does Axos Financial generate each year?

Axos Financial (NYSE:AX) has a recorded annual revenue of $1.28 billion.

How much profit does Axos Financial generate each year?

Axos Financial (NYSE:AX) has a recorded net income of $307.17 million. AX has generated $6.78 earnings per share over the last four quarters.

What is Axos Financial's price-to-earnings ratio?

Axos Financial (NYSE:AX) has a trailing price-to-earnings ratio of 7.42 and a forward price-to-earnings ratio of 7.80.

What is Axos Financial's EPS forecast for next year?

Axos Financial's earnings are expected to grow from $6.45 per share to $6.94 per share in the next year, which is a 7.60% increase.


More Earnings Resources from MarketBeat

This page (NYSE:AX) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners